MediWound Ltd. (MDWD)

NASDAQ: MDWD · IEX Real-Time Price · USD
1.46
+0.07 (5.04%)
At close: Oct 3, 2022 4:00 PM
1.39
-0.07 (-4.79%)
After-hours: Oct 3, 2022 4:04 PM EDT
5.04%
Market Cap 59.45M
Revenue (ttm) 20.93M
Net Income (ttm) -15.45M
Shares Out 40.72M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 136,444
Open 1.44
Previous Close 1.39
Day's Range 1.33 - 1.52
52-Week Range 1.21 - 4.01
Beta 0.96
Analysts Buy
Price Target 6.46 (+342.5%)
Earnings Date Nov 14, 2022

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the trea... [Read more...]

Industry Pharmaceuticals
IPO Date Mar 20, 2014
CEO Sharon Malka
Employees 77
Stock Exchange NASDAQ
Ticker Symbol MDWD
Full Company Profile

Financial Performance

In 2021, MediWound's revenue was $23.76 million, an increase of 9.19% compared to the previous year's $21.76 million. Losses were -$13.55 million, 47.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MDWD stock is "Buy." The 12-month stock price forecast is 6.46, which is an increase of 342.47% from the latest price.

Price Target
$6.46
(342.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximatel...

YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tiss...

1 week ago - GlobeNewsWire

EMA Accepts MediWound's Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Ther...

Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burns Upon approval, NexoBrid will serve as a safe and effective non-surgical ...

1 week ago - GlobeNewsWire

MediWound's NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue...

3 weeks ago - GlobeNewsWire

MediWound (MDWD) Reports Q2 Loss, Misses Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 11.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

Positive Results in Two Phase 2 Trial s of EscharEx

1 month ago - GlobeNewsWire

MediWound Enhances Its Board and Executive Leadership Team

Mr. N achum Shamir appointed as Chairman of the Board

1 month ago - GlobeNewsWire

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe The...

Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023 Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023

2 months ago - GlobeNewsWire

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MediWound Schedules Second Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET

2 months ago - GlobeNewsWire

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Car...

MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept

2 months ago - GlobeNewsWire

MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and reg...

2 months ago - GlobeNewsWire

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Le...

EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUs Data Demonstrate s EscharEx Reduce d Wound Size, Biofilm and Bacterial Burden

2 months ago - GlobeNewsWire

MediWound to Host a Key Opinion Leader Investor Day on EscharEx

In-Person KOL Breakfast Meeting to be held on Tuesday, July 12th in New York City In-Person KOL Breakfast Meeting to be held on Tuesday, July 12th in New York City

2 months ago - GlobeNewsWire

MediWound Names Mr. Tzvi Palash as Chief Operating Officer

Brings Extensive Operational Experience from International Pharmaceutical Companies Brings Extensive Operational Experience from International Pharmaceutical Companies

3 months ago - GlobeNewsWire

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

MediWound Announces CEO Transition

Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30

4 months ago - GlobeNewsWire

MediWound Reports First Quarter 2022 Financial Results

Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

4 months ago - GlobeNewsWire

MediWound Posts Promising EscharEx Data For Chronic Wounds

MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs).  The study met its primary and secondary endpoints an...

4 months ago - Benzinga

MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

Study Met Primary and Key Secondary Endpoints with Statistically Significant Results  Compared to Control Arms

4 months ago - GlobeNewsWire

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022

YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and reg...

4 months ago - GlobeNewsWire

MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Sprin...

The poster, featuring the phase 2 pharmacology study promising results, was selected and featured during the Grand Rounds Session of the SAWC Wound Care Learning Network The poster, featuring the phase ...

5 months ago - GlobeNewsWire

MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022

Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds

6 months ago - GlobeNewsWire

MediWound Announces Exercise of Over-Allotment Option

YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-thera...

6 months ago - GlobeNewsWire

MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds

Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022

6 months ago - GlobeNewsWire

MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research